{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SOC+Arm&page=2", "query": { "intervention": "SOC Arm", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SOC+Arm&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T16:30:51.287Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06532279", "title": "Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Head and Neck Squamous Cell Carcinoma", "Hypopharyngeal Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Nasopharyngeal Squamous Cell Carcinoma", "Oral Cavity Squamous Cell Carcinoma", "Oropharyngeal Squamous Cell Carcinoma", "Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage 0 Hypopharyngeal Carcinoma AJCC v8", "Stage 0 Nasopharyngeal Carcinoma AJCC v8", "Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage I Hypopharyngeal Carcinoma AJCC v8", "Stage I Laryngeal Cancer AJCC v8", "Stage I Lip and Oral Cavity Cancer AJCC v8", "Stage I Nasopharyngeal Carcinoma AJCC v8", "Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage II Hypopharyngeal Carcinoma AJCC v8", "Stage II Laryngeal Cancer AJCC v8", "Stage II Lip and Oral Cavity Cancer AJCC v8", "Stage II Nasopharyngeal Carcinoma AJCC v8", "Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Nasopharyngeal Carcinoma AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Nasopharyngeal Carcinoma AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Hypopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Lip and Oral Cavity Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stomatitis" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Image Guided Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "MnSOD Mimetic BMX-001", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2025-06-23", "completion_date": "2032-01-01", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-18T16:30:51.287Z", "location_count": 153, "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 126 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06532279" }, { "nct_id": "NCT04828824", "title": "Premature Discontinuation of Contraceptive Implants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Contraception Behavior" ], "interventions": [ { "name": "Ethinyl Estradiol / Norgestimate Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "14 Years", "maximum_age": "23 Years", "sex": "FEMALE", "summary": "14 Years to 23 Years · Female only" }, "enrollment_count": 600, "start_date": "2021-06-18", "completion_date": "2025-11-12", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-18T16:30:51.287Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04828824" }, { "nct_id": "NCT03301597", "title": "NLA101 in Adults Receiving High Dose Chemotherapy for AML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "NLA101", "type": "BIOLOGICAL" }, { "name": "Standard of Care (SOC) chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nohla Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2018-01-24", "completion_date": "2019-03-18", "has_results": false, "last_update_posted_date": "2021-03-30", "last_synced_at": "2026-09-18T16:30:51.287Z", "location_count": 25, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 19 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03301597" }, { "nct_id": "NCT05632562", "title": "Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "High Grade Glioma" ], "interventions": [ { "name": "O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "10 Years to 89 Years" }, "enrollment_count": 20, "start_date": "2024-03-07", "completion_date": "2028-02-01", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-18T16:30:51.287Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05632562" }, { "nct_id": "NCT00488059", "title": "A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "enfuvirtide [Fuzeon]", "type": "DRUG" }, { "name": "Optimized background ARV", "type": "DRUG" }, { "name": "Integrase inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2007-06", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2011-07-22", "last_synced_at": "2026-09-18T16:30:51.287Z", "location_count": 41, "location_summary": "Hobson City, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more", "locations": [ { "city": "Hobson City", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00488059" }, { "nct_id": "NCT04370262", "title": "Multi-site Adaptive Trials for COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "SOC + Intravenous Famotidine", "type": "DRUG" }, { "name": "SOC + Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 233, "start_date": "2020-04-07", "completion_date": "2020-09-07", "has_results": false, "last_update_posted_date": "2020-12-11", "last_synced_at": "2026-09-18T16:30:51.287Z", "location_count": 5, "location_summary": "Bay Shore, New York • Manhasset, New York • Mount Kisco, New York + 2 more", "locations": [ { "city": "Bay Shore", "state": "New York" }, { "city": "Manhasset", "state": "New York" }, { "city": "Mount Kisco", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Queens", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04370262" }, { "nct_id": "NCT05168306", "title": "T2 FSL2 Weight Loss", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "FreeStyle Libre 2 Flash Glucose Monitoring System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abbott Diabetes Care", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "30 Years to 70 Years" }, "enrollment_count": 43, "start_date": "2021-12-05", "completion_date": "2023-07-19", "has_results": false, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-09-18T16:30:51.287Z", "location_count": 1, "location_summary": "Renton, Washington", "locations": [ { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05168306" }, { "nct_id": "NCT06058377", "title": "Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "HER2-Negative Breast Carcinoma", "Hormone Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Genetic Testing", "type": "OTHER" }, { "name": "Mammography", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3680, "start_date": "2023-11-27", "completion_date": "2032-05-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-09-18T16:30:51.287Z", "location_count": 554, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 426 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06058377" }, { "nct_id": "NCT03948360", "title": "Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Burn Wound" ], "interventions": [ { "name": "Low-Irradiance Monochromatic Biostimulation (LIMB) Device", "type": "DEVICE" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Rogers Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 12, "start_date": "2017-09-07", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2019-05-13", "last_synced_at": "2026-09-18T16:30:51.287Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03948360" }, { "nct_id": "NCT04575610", "title": "IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "PF-06650833", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 7, "start_date": "2020-11-27", "completion_date": "2021-10-06", "has_results": false, "last_update_posted_date": "2021-10-26", "last_synced_at": "2026-09-18T16:30:51.287Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04575610" } ] }